In an attempt to diversify its pipeline, Incyte has signed a strategic collaboration with Genesis Therapeutics to develop small molecule medicines leveraging the latter’s artificial intelligence (AI) technologies. Through the deal, which involves an upfront payment of US$30M and up to US$295 M per target in milestones, the companies will utilise Genesis’ AI platform, GEMS (Genesis Exploration of Molecular Space) to discover breakthrough small molecule therapeutics against two initial Incyte-selected targets. The deal marks yet another high-profile partnership for Genesis, which has previously formed alliances with Genentech, Lilly and Gilead Sciences.